Pharvaris is a pre-revenue biotechnology company advancing its lead asset, PHA121, for hereditary angioedema, with its investment thesis hinged on the successful Phase 3 clinical execution and potential commercial launch.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 12, 2026 | -$0.81-8.5% vs -$0.75 | — vs — |
Q2 2026 May 12, 2026 | -$0.70+14.8% vs -$0.82 | — vs — |
Q2 2026 Apr 2, 2026 | -$0.85-18.3% vs -$0.71 | — vs — |
Q4 2025 Nov 12, 2025 | -$0.70+10.3% vs -$0.78 | — vs — |
Pivotal, Phase 3 CHAPTER-3 data selected for late-breaking oral presentation on Saturday, November 14 Pivotal, Phase 3 CHAPTER-3 data selected for late-breaking oral presentation on Saturday, November 14
Bank of America Securities on Friday upgraded Pharvaris N.V. (NASDAQ:PHVS), citing an attractive entry point with clinical risk largely removed.
ZUG, Switzerland, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema, such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that results of RAPIDe-3, a phase 3, global, randomized, double-blind, placebo-controlled crossover study evaluating oral deucrictibant immediate-release (IR) capsule (20 mg) for the on-demand treatment of HAE attacks in adolescents and adults have been published in The Lancet (Journal Impact Factor: 109.0).
Findings highlight opportunities for further improvement in treatment use and adherence, despite the availability of multiple long-term prophylaxis and on-demand treatment options Findings highlight opportunities for further improvement in treatment use and adherence, despite the availability of multiple long-term prophylaxis and on-demand treatment options
Benchmark PHVS against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Pharvaris N.V. (PHVS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $34.39 | $2.4B | -12.24 | — | — | -61.24% | — | |
| $277.62 | $7.74B | -23.85 | -100% | — | -34.15% | — | |
| $2.88 | $711.44M | -12.98 | 22.09% | -11.85% | -35.3% | — | |
| $39.42 | $6.55B | -11.55 | 33.87% | -64.64% | -110.84% | — | |
| $11.31 | $695.09M | -3.40 | — | — | -52.89% | — | |
| $271.83 | $44.74B | 32.57 | 5.87% | 8.05% | 21.39% | — |
Pharvaris N.V. (PHVS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when PHVS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Pharvaris N.V. (PHVS) stock FAQ — growth, dividends, profitability & financials explained
No. Pharvaris N.V. (PHVS) reported a net loss of $171.6M over the trailing twelve months.
Pharvaris N.V. (PHVS) had a return on equity (ROE) of -61.2% over the trailing twelve months. A negative ROE means the company lost money over the period.
Pharvaris N.V. (PHVS) had negative free cash flow of $156.1M over the trailing twelve months.
